LONDON, June 03, 2021 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult…


Previous articlePsychedelics: A New Fountain of Youth?
Next articleMindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine